A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

This trial tests a combination of cancer-fighting drugs — BL-B01D1 (a targeted antibody-drug), pembrolizumab (an immunotherapy), and optionally bevacizumab (a drug that cuts off tumor blood supply) — in women with cervical cancer or endometrial (uterine) cancer that has come back or spread. **You may be eligible if...** - You are a woman aged 18–75 with cervical or endometrial cancer that has returned or spread - Your cancer has been confirmed by biopsy or cell testing - You have at least one measurable tumor - Your overall health is reasonably good (ECOG 0–1) - You have not been pregnant within 7 days of starting treatment and agree to use contraception during and for 6 months after treatment **You may NOT be eligible if...** - You have previously received certain targeted antibody-drug treatments for this cancer - You have active autoimmune disease or another active cancer - You have a serious heart, liver, or kidney condition - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.